A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
Medium urgency

US-CONGRESS BILLS-119hr9682ih: Cure Hepatitis C Act of 2026

Detected July 17, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

The Cure Hepatitis C Act of 2026 aims to increase access to hepatitis C treatments by streamlining FDA approval processes and addressing drug shortages. It may impact cGMP compliance, ANDA approvals, and DEA quotas for related APIs.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 17, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Upon enactment (likely 2026); monitor legislative progress for specific deadlines.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

The bill proposes expedited FDA review for hepatitis C drugs, potential changes to DEA quotas for related APIs, and new requirements for cGMP compliance to prevent shortages.

Who it affects

Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)

What you must do

Review current hepatitis C product pipelines and assess impact on ANDA/NDA filings; monitor DEA quota adjustments for APIs; update cGMP protocols to align with potential new standards.

Deadline

Upon enactment (likely 2026); monitor legislative progress for specific deadlines.

Source: https://www.govinfo.gov/app/details/BILLS-119hr9682ih

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)